grant
Next generation T cell therapies for mutant KRAS solid tumors
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Sept 2025Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY202521+ years oldAblationAddressAdoptive Cell TransfersAdultAdult HumanAfter CareAfter-TreatmentAftercareAllelesAllelomorphsAntigenic DeterminantsBinding DeterminantsBiotechBiotechnologyBlood leukocyteC-K-RASCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCRISPR approachCRISPR based approachCRISPR methodCRISPR methodologyCRISPR techniqueCRISPR technologyCRISPR toolsCRISPR-CAS-9CRISPR-based methodCRISPR-based techniqueCRISPR-based technologyCRISPR-based toolCRISPR/CAS approachCRISPR/Cas methodCRISPR/Cas technologyCRISPR/Cas9CRISPR/Cas9 technologyCancer PatientCancersCas nuclease technologyCase StudyCell BodyCell Growth in NumberCell MultiplicationCell ProliferationCell TherapyCellsCellular ExpansionCellular GrowthCellular ProliferationCellular immunotherapyClinicClinicalClinical EvaluationClinical TestingClinical TrialsClustered Regularly Interspaced Short Palindromic Repeats approachClustered Regularly Interspaced Short Palindromic Repeats methodClustered Regularly Interspaced Short Palindromic Repeats methodologyClustered Regularly Interspaced Short Palindromic Repeats techniqueClustered Regularly Interspaced Short Palindromic Repeats technologyCodonCodon NucleotidesCollaborationsCommon Rat StrainsCorrelative StudyDNA AlterationDNA Sequence AlterationDataDevelopmentDoseDrug CombinationsEffector CellEligibilityEligibility DeterminationEngineeringEnsureEpitopesGene ModifiedGene TranscriptionGenesGenetic AlterationGenetic TranscriptionGenomicsGoalsHLA-AHLA-A geneHLA-CHLA-C AntigensHLAAHumanImmuneImmune TargetingImmune systemImmunesImmunologyImmunooncologyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectIn VitroInvestigatorsK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKi-RASLYT3LaboratoriesLesionLeukocytesLeukocytes Reticuloendothelial SystemMHC ReceptorMajor Histocompatibility Complex ReceptorMalignant NeoplasmsMalignant Soft Tissue NeoplasmMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMarrow leukocyteMethodsMissense MutationModern ManMutateMyelogenousMyeloidMyeloid CellsNeoplasm Circulating CellsOncogene K-RasOncogene ProductsOncogene ProteinsOncoproteinsPatientsPennsylvaniaPharmaceutical AgentPharmaceuticalsPharmacologic SubstancePharmacological SubstancePhase I StudyPhenotypePopulationProductivityProteomicsProtocol ScreeningPublishingPulmonary CancerPulmonary malignant NeoplasmRASK2RNA ExpressionRatRats MammalsRattusReagentReceptor ProteinRecurrenceRecurrentResearchResearch PersonnelResearch ResourcesResearchersResistanceResourcesSafetySarcomaSequence AlterationSiteSolid NeoplasmSolid TumorSpinal ColumnSpineT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell infiltrationT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell Antigen ReceptorsT-Cell ReceptorT-CellsT-LymphocyteT-cell receptor repertoireT-cell therapeuticsT-cell transfer therapyT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTCR repertoireTechnology TransferTestingTranscriptionTranslationsTumor AntigensTumor-Associated AntigenUniversitiesVariantVariationVertebral columnVirusWhite Blood CellsWhite CellWorkadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyadoptive cell therapyadoptive cellular therapyadulthoodbackbonebase editingbiomarker developmentbiomarker discoverycancer antigenscancer clinical trialcancer microenvironmentcase reportcell based interventioncell growthcell mediated interventioncell mediated therapiescell-based immunotherapycell-based therapeuticcell-based therapycellular therapeuticcellular therapychild patientscirculating neoplastic cellcirculating tumor cellclinical testclinical translationclinically translatablecostdesigndesigningdevelopmentalengineered T cellsexhaustiongene editing methodgene editing methodologygene editing platformgene editing strategygene editing systemgene editing techniquesgene editing technologygene editing toolsgene modificationgene-editing approachgene-editing toolkitgenetically engineered T-cellsgenetically modifiedgenomic alterationimmune cell therapyimmune suppressionimmune suppressive activityimmune suppressive functionimmune-oncologyimmuno oncologyimmunology oncologyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedin vivoinsightlead candidatelung cancermalignancymalignant soft tissue tumormanufacturemissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmolecular biomarkermolecular markermolecular pathologymulti-site trialmultisite trialmutantneo-antigenneo-epitopesneoantigensneoepitopesneoplasm/cancernext generationnoveloncoimmunologyoncology clinical trialpediatric patientsperipheral bloodpersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentpharmaceuticalphase 1 studypost treatmentprecancerprecancerouspremalignantreceptorresearch clinical testingresistance mechanismresistantresistant mechanismresponsesafety engineeringsingle cell technologysmall molecular inhibitorsmall molecule inhibitorsuccesstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttechnological innovationtherapeutic T-cell platformthymus derived lymphocytetransgenic T- cellstranslationtumortumor microenvironmenttumor-specific antigenv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologwhite blood cellwhite blood corpuscle
Description preview
Project Summary
This proposal “Next generation T cell therapies for KRAS mutated solid tumors” was developed in response to
RFA-CA-22-028 and to fulfill the Cancer Adoptive Cellular Therapy Network (Can-ACT) objectives. The focus of
our proposal is targeting mutant KRAS, a clonal driver oncoprotein, by the early-stage clinical testing of
TCR1020,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click